

David L. Banks, Pharm.D., BCGP

228 Strawbridge Drive
Moorestown, NJ, 08057
Office: 888-974-2763 ext 6547
Cell: 609-351-7978
E-mail: dbankes@trhc.com

EDUCATION

8/2007 – 5/2013 **Doctor of Pharmacy**
Summa Cum Laude (GPA 3.89/4.00)
University of the Sciences – Philadelphia College of Pharmacy

PROFESSIONAL WORK EXPERIENCE

11/2018 – Present **Research Pharmacist**
Tabula Rasa HealthCare, Moorestown, NJ

12/2016 – 11/2018 **Clinical Pharmacist: Enhanced Medication Therapy Management**
Tabula Rasa HealthCare, Moorestown, NJ

1/2014 – 12/2016 **Clinical Pharmacist: Programs of All-Inclusive Care for the Elderly**
Tabula Rasa HealthCare (d/b/a CareKinesis, Inc.), Moorestown, NJ

9/2013 – 12/2013 **Staff Pharmacist**
Rite Aid Pharmacy, Chestertown, MD

8/2013 – 9/2013 **Float Pharmacist**
Rite Aid Pharmacy, New Castle, DE (District HQ)

4/2013 – 8/2013 **Intern Pharmacist**
Rite Aid Pharmacy, Wilmington, DE

6/2010 – 4/2013 **Student Intern Pharmacist**
ACME Sav-On Pharmacy, Mt. Holly, NJ

PUBLISHING

Peer – Reviewed:

1. Wright SA, Bardolia C, **Banks D**, Amin N, Turgeon J. Angiotensin Converting Enzyme (ACE) Inhibitor-Induced Cough Resulting in Prescribing Cascade. *Clin Case Reports*. 2020;10(7). DOI: 10.37421/jccr.2020.10.1368

2. **Bankes DL**, Jin H, Finnel S, Michaud V, Knowlton CH, Turgeon J, Stein A. Association of a Novel Medication Risk Score with Adverse Drug Events and Other Pertinent Outcomes Among Participants of the Programs of All-Inclusive Care for the Elderly. *Pharmacy (Basel)*. 2020 May 20;8(2):E87. (PMID: 32443719).
3. Matos A, Bain KT, **Bankes DL**, Furman A, Skalski B, Verzicco J, Turgeon J. Cytochrome P450 (CYP450) Interactions Involving Atypical Antipsychotics are Common in Community-Dwelling Older Adults Treated for Behavioral and Psychological Symptoms of Dementia. *Pharmacy (Basel)*. 2020 Apr 8;8(2):E63. (PMID: 32276526).
4. **Bankes DL**, Schamp RO, Knowlton CH, Bain KT. Prescriber-Initiated Engagement of Pharmacists for Information and Intervention in Programs of All-Inclusive Care for the Elderly. *Pharmacy (Basel)*. 2020 Feb 21;8(1):24. (PMID: 32098064).
5. **Bankes DL**, Amin NS, Bardolia C, Awadalla MS, Knowlton CH, Bain KT. Medication-related problems encountered in the Program of All-Inclusive Care for the Elderly: An observational study. *J Am Pharm Assoc*. 2020 Mar-Apr;60(2):319-327. Epub 2019 Dec 16. (PMID: 31859218).

RESEARCH IN PROGRESS

1. Opioids, Polypharmacy, and Drug Interactions: A Technological Paradigm Shift is Needed to Ameliorate the Ongoing Opioid Epidemic. *Primary Investigator*: Adriana Matos; *Co-Investigator*: David Bankes
2. Predicting Adverse Drug Events, Hospitalizations, and Emergency Department Visits in PACE: A Comparison of the MedWise Risk Score and Hierarchical Condition Category Scores. *Primary Investigator*: David Bankes
3. Assessing the Impact of Pharmacists' Clinical Interventions on Various Clinical and Economic Outcomes in the Enhanced MTM program. *Primary Investigator*: Alan Stein; *Co-Investigator*: David Bankes
4. Assessing the Impact of Pharmacists' Clinical Interventions on Various Clinical and Economic Outcomes in PACE. *Primary Investigator*: Alan Stein; *Co-Investigator*: David Bankes
5. Reduction in Anticholinergic Burden Related to Bladder Antimuscarinics for Patients in a PACE Setting. *Primary Investigator*: David Bankes
6. PACE Organization Attributes Associated with Economic and Clinical Outcomes. This study intends to answer the following question: "what characteristics seem to be associated with better outcomes in PACE?" *Primary Investigator*: David Bankes
7. The Impact of Pharmacist-Delivered Comprehensive Medication Reviews on Quality of Life Scores for Patients in a Federally Qualified Health Center Setting. *Primary Investigator*: Jennifer Bingham; *Co-Investigator*: David Bankes
8. A Critical Appraisal of Drug-Drug Interaction Databases. This study seeks to compare the types of drug interactions identified by three commercially available DDI software. *Primary Investigator*: Veronique Michaud; *Co-Investigator*: David Bankes

9. Tamsulosin associated dizziness identified by pharmacists in an Enhanced MTM program.
Primary Investigator: David Banks

PEER REVIEWER

Clinical Toxicology

CLINICAL DEVELOPMENT

Automated Rules Written for Software (MedWise Advisor™) Implementation

6/2020	Awadalla MS, Banks DL, Dhanda J, Gilbert S, Raymond S, Turgeon J. Competitive inhibition of trazodone at CYP3A4.
6/2020	Awadalla MS, Banks DL, Dhanda J, Gilbert S, Raymond S, Turgeon J. Non-competitive inhibition of trazodone at CYP3A4.
6/2020	Awadalla MS, Banks DL, Dhanda J, Gilbert S, Raymond S, Turgeon J. Drug holiday for oral bisphosphonate as outlined by Endocrine Society Clinical Practice Guideline for Osteoporosis.
6/2020	Awadalla MS, Banks DL, Dhanda J, Gilbert S, Raymond S, Turgeon J. Competitive inhibition of rivaroxaban at CYP3A4.
6/2020	Awadalla MS, Banks DL, Dhanda J, Gilbert S, Raymond S, Turgeon J. Competitive inhibition of apixaban at CYP3A4.
5/2020	Awadalla MS, Banks DL, Dhanda J, Gilbert S, Raymond S, Turgeon J. Induction of rivaroxaban at CYP3A4.
5/2020	Awadalla MS, Banks DL, Dhanda J, Gilbert S, Raymond S, Turgeon J. Induction of apixaban at CYP3A4.
5/2020	Awadalla MS, Banks DL, Dhanda J, Gilbert S, Raymond S, Turgeon J. Gradual dose reduction of antipsychotics for behavioral and psychotic symptoms of dementia.
5/2020	Awadalla MS, Banks DL, Dhanda J, Gilbert S, Raymond S, Turgeon J. Dual use of sulfonylurea and rapid-acting insulin.
4/2020	Awadalla MS, Banks DL, Dhanda J, Gilbert S, Raymond S, Turgeon J. Long acting sulfonylureas (glyburide and glimepiride) use in older adults.
4/2020	Awadalla MS, Banks DL, Dhanda J, Gilbert S, Raymond S, Turgeon J. Competitive inhibition of citalopram at CYP2C19.

- 4/2020 Awadalla MS, Bankes DL, Dhanda J, Gilbert S, Raymond S, Turgeon J.
Non-competitive inhibition of citalopram at CYP2C19.
- 4/2020 Awadalla MS, Bankes DL, Dhanda J, Gilbert S, Raymond S, Turgeon J.
Competitive inhibition of escitalopram at CYP2C19.
- 4/2020 Awadalla MS, Bankes DL, Dhanda J, Gilbert S, Raymond S, Turgeon J.
Non-competitive inhibition of escitalopram at CYP2C19.

PROFESSIONAL PRESENTATIONS

Accredited Continuing Education Faculty

- 10/2019 Bankes DL. **“Medication-Related Falls: Evaluation and Application of the Current Literature.”** *As part of Tabula Rasa HealthCare University’s continuing education series, Moorestown, NJ*
- 11/2016 Bankes DL. **“Geriatric Pharmacotherapeutics: UTIs and SSTIs.”** *As part of Tabula Rasa HealthCare University’s continuing education series, Moorestown, NJ*
- 4/2016 Bankes DL. **“Dementia Pharmacotherapeutics”** *As part of Tabula Rasa HealthCare University’s continuing education series, Moorestown, NJ*

National, Local, and Other Formal Presentations

- 6/2017 Bankes DL and Gallo K. **“MRM Vectors and Case Discussions.”** *Presented various cases that showcased key aspects of TRHC’s clinical decision support system. Presented to future community pharmacy clients. Tabula Rasa Healthcare, Moorestown, NJ.*
- 10/2015 Bankes DL. **“Alzheimer’s Dementia-Related Agitation Management: Nuedexta.”** *Webinar presented to Brandman PACE clinical staff. CareKinesis, Moorestown, NJ*
- 10/2015 Bankes DL. **“Pharmacogenomics in Practice: Case Studies.”** *National PACE Association: 2015 National Conference, Philadelphia, PA*
- 9/2015 Bankes DL. **“Pharmacogenomics in Practice: Case Studies.”** *3 PGx cases were presented to PACE physicians and medical directors during CareKinesis’ Clinical Advisory Panel Annual Meeting, West Palm Beach, FL*
- 3/2015 Bankes DL. **“The Anticholinergic Burden of Proof: Dementia on Trial.”** *Webinar presented to various PACE clinical staff. CareKinesis, Moorestown, NJ.*
- 8/2014 & 9/2014 Bankes DL. **“Medication Management for UTIs: Take CaUTION.”** *Webinar presented twice to various PACE clinical staff. CareKinesis, Moorestown, NJ.*

12/2012 Bankes DL, George J, Pontiggia L, Sen S, Shah S, Thomas T,
 “Vancomycin-induced nephrotoxicity in hospitalized elderly.” *Abstract*
 poster presented during the 2012 ASHP Mid-Year Meeting. Las Vegas, NV.

CERTIFICATES, LICENSURE, & ADDITIONAL TRAINING

8/2013 – Present **Pharmacist: Delaware**
 License number: A1-0004441

8/2013 – Present **Pharmacist: Maryland**
 License number: 21867

12/2013 – Present **Pharmacist: Colorado**
 License number: PHA.0020184

1/2014 – Present **Pharmacist: New Jersey**
 License number: 28RI03619900

5/2016 – Present **Board Certified Geriatric Pharmacist (BCGP)**
 Credential number: 9104398

5/2012 – Present **Immunization Certified**
 American Pharmacists Association (CPN #202-0014)

Current thru 3/2021 **Basic Life Support Provider**
 American Heart Association

9/2018 – Present **Certified in Human Subjects Research**
 National Institutes of Health – Certification number 2888226

HONORS & AWARDS

5/2013 **GlaxoSmith Kline Commencement Award** – *scholastic cash award for demonstrating an ability to critically analyze patient cases and solve therapeutic problems*

5/2013 **Merck Award** – *scholastic award for outstanding academic achievement*

5/2013 **Alumni Association Award** – *scholastic award for graduating with the highest grade point average*

4/2011 **Rho Chi Honor Society**

4/2010 **Rho Chi Achievement Award Winner** – *awarded for having highest GPA entering P1 year*

PROFESSIONAL MEMBERSHIPS

American Society of Consultant Pharmacists
American Pharmacists Association